Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low serum IGF-1 and 25(OH)D levels may separately predict poor cognitive performance in patients with diabetes.
|
31319676 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-I and IGFBP-3 were not associated with the incidence of diabetes.
|
30898176 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, alterations in sex hormone, IGF1, glucose, and CML levels did not account for the inverse association of diabetes and prostate cancer risk.
|
31504635 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we examined the relationship between IGF-1 and liver fibrosis markers in type 2 diabetes patients without obvious alcoholic consumption and determined whether IGF-1 is associated with fibrosis of non-alcoholic fatty liver disease.
|
30592792 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer.
|
31847392 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intraperitoneal administration of IGF-1R inhibitor (glycogen synthase kinase-3β, GSK4529) from <i>week 8</i> to <i>week 16</i> postdiabetes induction ameliorated urinary albumin excretion and kidney histological changes due to diabetes, including amelioration of glomerulomegaly, inflammatory infiltration, and tubulointerstitial fibrosis.
|
31361542 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diabetes accompanying PDAC does not influence the level of IGF-1 as opposed to diabetes in the course of CP.
|
28499807 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Homozygous receptors for insulin and not IGF-1 accelerate intimal hyperplasia in insulin resistance and diabetes.
|
31562314 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Male C57BL/6J mice were administered streptozotocin(STZ) to induce diabetes and thus divided into 5 groups: the untreated group (DN group), the benazepril-treated group (BEN-DN group), the insulin-treated group (INS-DN group) and the IGF-1R inhibitor-treated group (IGF-DN group).
|
29384065 |
2018 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Poor metabolic control and diabetes duration impact negatively on serum IGF-I levels.
|
29663652 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with the control group, the diabetes group developed hypoalgesia after 12 weeks, and neurological lesions improved following an intraperitoneal injection of recombinant (r)IGF‑1.
|
30221656 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetes was induced with streptozocin in both LI-IGF-I-/- and control mice.
|
29534073 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upon multivariate analysis, diabetes was associated with an IGF-1 at diagnosis >2× upper limit of normal, with the persistence of active acromegaly, the presence of hypertension upon the last visit, with the presence of a macroadenoma, and with female sex.
|
29618021 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
After 8 weeks, the type 2 diabetes nephropathy model was successfully set up the different drugs were administrated to mice with diabetes (insulin 1-2 U/day, benazepril 10 mg/kg per day intragastrically, IGF-1R inhibitor 30 mg/kg per day intragastrically).
|
30254418 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Examine differences in GH-IGF-1 axis between T1D on subcutaneous insulin treatment and matched controls without diabetes and possible associations between GH-IGF-1 axis and UEI.
|
29989677 |
2018 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low serum IGF-1 levels are associated with increased histologic severity of NAFLD when rigorously controlled for age, BMI, the presence of diabetes, and after the exclusion of subjects with cirrhosis.
|
28125073 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the epidermis, IL-15, IGF-1, and mTOR are known to regulate the maintenance of DETCs; however, it is unclear how these molecules may intersect to regulate DETC homeostasis in diabetes.
|
28729536 |
2017 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared to patients without polyps, subjects with polyps were somewhat older and had significantly higher insulin-like growth factor-1 (IGF-1) levels and a higher prevalence of diabetes.
|
28225314 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth factor signaling via insulin receptor (IR) and IGF-1 receptor (IGF1R) plays several important roles in the pathogenesis of metabolic syndrome and diabetes.
|
28646158 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The insulin-like growth factor 1 (IGF1) pathway has been linked with various diseases including diabetes, cancer and aging.
|
28500773 |
2017 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AAV-mediated pancreatic-specific overexpression of IGF1 in adult animals also dramatically reduced diabetes incidence, both when vectors were delivered before pathology onset or once insulitis was established.
|
28702323 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The difference of serum IGF-I and IGFBP-3 levels between patients with T2DM and subjects without diabetes showed that IGF-I may be a useful marker for diabetes mellitus and IGFBP-3 for possible complications of this affection.
|
29250665 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review discussed specifically the role of IR isoforms as well as IGF-IR in diabetes and its associated complications as obesity and atherosclerosis.
|
29201918 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess whether IGF-I and IGFBP-3 are associated with a higher risk of incident diabetes in older adults.
|
29040592 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main data search terms were: Na+/K+-ATPase; estradiol and Na+/K+-ATPase; estradiol, Na+/K+-ATPase and CVS; estradiol, Na+/K+-ATPase and CVD; estradiol, Na+/K+- ATPase and obesity; estradiol, Na+/K+-ATPase and diabetes; estradiol, Na+/K+-ATPase and hypertension; IGF-1; IGF-1 and Na+/K+-ATPase; IGF-1, Na+/K+-ATPase and CVS; IGF-1, Na+/K+-ATPase and CVD; IGF-1, Na+/K+- ATPase and obesity; IGF-1, Na+/K+-ATPase and diabetes; IGF-1, Na+/K+-ATPase and hypertension.
|
28164755 |
2017 |